These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31417310)

  • 1. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.
    Hou H; Qin K; Liang Y; Zhang C; Liu D; Jiang H; Liu K; Zhu J; Lv H; Li T; Zhang X
    Cancer Manag Res; 2019; 11():5665-5675. PubMed ID: 31417310
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of
    Canale M; Petracci E; Delmonte A; Chiadini E; Dazzi C; Papi M; Capelli L; Casanova C; De Luigi N; Mariotti M; Gamboni A; Chiari R; Bennati C; Calistri D; Ludovini V; Crinò L; Amadori D; Ulivi P
    Clin Cancer Res; 2017 May; 23(9):2195-2202. PubMed ID: 27780855
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluate the Prognosis of
    Cao J; J Gu J; Liang Y; Wang B
    Technol Cancer Res Treat; 2022; 21():15330338221138213. PubMed ID: 36524293
    [No Abstract]   [Full Text] [Related]  

  • 5. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.
    Roeper J; Falk M; Chalaris-Rißmann A; Lueers AC; Ramdani H; Wedeken K; Stropiep U; Diehl L; Tiemann M; Heukamp LC; Otto-Sobotka F; Griesinger F
    Oncotarget; 2020 Jan; 11(3):250-264. PubMed ID: 32076486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.
    Tang M; Wang S; Zhao B; Wang W; Zhu Y; Hu L; Zhang X; Xiong S
    Med Sci Monit; 2019 Nov; 25():8430-8437. PubMed ID: 31704907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon
    Tan J; Hu C; Deng P; Wan R; Cao L; Li M; Yang H; Gu Q; An J; Jiang J
    Front Oncol; 2021; 11():646577. PubMed ID: 34513661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant
    Canale M; Petracci E; Delmonte A; Bronte G; Chiadini E; Ludovini V; Dubini A; Papi M; Baglivo S; De Luigi N; Verlicchi A; Chiari R; Landi L; Metro G; Burgio MA; Crinò L; Ulivi P
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32272775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis.
    Lan B; Zhao N; Du K; Leng B
    Oncol Lett; 2022 Nov; 24(5):384. PubMed ID: 36238360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma
    Wang X; Liu Y; Meng Z; Wu Y; Wang S; Jin G; Qin Y; Wang F; Wang J; Zhou H; Su X; Fu X; Wang X; Shi X; Wen Z; Jia X; Qin Q; Gao Y; Guo W; Lu S
    Ann Transl Med; 2021 Apr; 9(8):635. PubMed ID: 33987333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
    Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
    J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
    [No Abstract]   [Full Text] [Related]  

  • 14. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer.
    Jiang H; Zhu M; Li Y; Li Q
    Mol Clin Oncol; 2019 Sep; 11(3):301-308. PubMed ID: 31384460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent
    Qin Z; Zhang H; Yan P; Yu L; Hong C; Calvetti L; Passaro A; Araujo A; Chen Y
    J Thorac Dis; 2023 Jul; 15(7):4016-4026. PubMed ID: 37559636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs.
    Gu W; Liu P; Tang J; Lai J; Wang S; Zhang J; Xu J; Deng J; Yu F; Shi C; Qiu F
    Front Oncol; 2023; 13():1288468. PubMed ID: 38375203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
    Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
    Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.